KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Equity Income (2021 - 2025)

Thermo Fisher Scientific's Equity Income history spans 5 years, with the latest figure at -$32.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Income fell 196.97% year-over-year to -$32.0 million, compared with a TTM value of -$42.0 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of -$41.0 million, up 2.38% over the prior year.
  • Equity Income for Q4 2025 was -$32.0 million at Thermo Fisher Scientific, down from $2.0 million in the prior quarter.
  • The five-year high for Equity Income was $33.0 million in Q4 2024, with the low at -$84.0 million in Q2 2024.
  • Average Equity Income over 5 years is -$17.7 million, with a median of -$15.0 million recorded in 2023.
  • Year-over-year, Equity Income tumbled 5000.0% in 2022 and then surged 3400.0% in 2024.
  • Tracing TMO's Equity Income over 5 years: stood at -$3.0 million in 2021, then tumbled by 900.0% to -$30.0 million in 2022, then surged by 96.67% to -$1.0 million in 2023, then surged by 3400.0% to $33.0 million in 2024, then crashed by 196.97% to -$32.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Equity Income are -$32.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).